These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27072807)

  • 1. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
    Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
    Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
    Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
    Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Pasz-Walczak G; Sek P; Piekarski J; Szwalski J; Spych M; Chałubińska-Fendler J; Suzin J; Tyliński W; Jeziorski A
    Ginekol Pol; 2013 Feb; 84(2):95-101. PubMed ID: 23668054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC).
    Bernardini MQ; Gien LT; Lau S; Altman AD; Gilks B; Ferguson SE; Köbel M; Samouëlian V; Wesa M; Cameron A; Nelson G; Han G; Clarke B; Ho TC; Panzarella T; Atenafu EG; McAlpine JN
    Gynecol Oncol; 2016 Apr; 141(1):148-54. PubMed ID: 26854651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
    Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
    Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
    Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
    Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
    Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.